Cargando…
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Autor principal: | Kudo, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999599/ https://www.ncbi.nlm.nih.gov/pubmed/36909143 http://dx.doi.org/10.1159/000528979 |
Ejemplares similares
-
All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy
por: Kudo, Masatoshi
Publicado: (2023) -
Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023) -
Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022) -
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2023) -
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
por: Kudo, Masatoshi
Publicado: (2023)